Here are the 10-K annual reports from Lifeward Ltd. (LFWD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow LFWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFWD filings page.
Lifeward Ltd. reports its 2025 annual business overview as a specialized neurorehabilitation and mobility medical device company. The company sells ReWalk powered exoskeletons for spinal cord injury, ReStore soft exo-suits for stroke rehab, and AlterG Anti-Gravity systems used in over 6,000 facilities globally.
Lifeward highlights U.S. and European reimbursement progress, including Medicare’s brace benefit classification for personal exoskeletons and a final DMEPOS fee schedule amount of $91,032 per device under HCPCS code K1007. Veterans Health Administration policies and German statutory insurer contracts continue to support case-by-case coverage.
Strategically, Lifeward agreed to acquire Oratech Pharma from Oramed in a share and warrant deal that will give Oramed up to 49.99% of Lifeward’s fully diluted equity and 4% revenue sharing on ReWalk products, alongside up to $20.0 million of senior secured convertible notes and high-interest bridge loans. Additional moves include a Skelable IP acquisition for upper-limb robotics and new distribution agreements with CorLife for U.S. workers’ compensation and Verita Neuro for select international markets.